





Review

# Current Hydration Habits: The Disregarded Factor for the Development of Renal and Cardiometabolic Diseases

Richard J. Johnson <sup>1</sup>, Fernando E. García-Arroyo <sup>2</sup>, Guillermo Gonzaga-Sánchez <sup>2</sup>, Kevin A. Vélez-Orozco <sup>2</sup>, Yamnia Quetzal Álvarez-Álvarez <sup>2</sup>, Omar Emiliano Aparicio-Trejo <sup>2</sup> , Edilia Tapia <sup>2</sup>, Horacio Osorio-Alonso <sup>2</sup> , Ana Andrés-Hernando <sup>3</sup>, Takahiko Nakagawa <sup>4</sup>, Masanari Kuwabara <sup>5,6</sup> , Mehmet Kanbay <sup>7</sup> , Miguel A. Lanaspá <sup>3</sup> and Laura Gabriela Sánchez-Lozada <sup>2,\*</sup>

- <sup>1</sup> Division of Renal Diseases and Hypertension, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA; richard.johnson@cuanschutz.edu
- <sup>2</sup> Department Cardio-Renal Physiopathology, INC Ignacio Chávez, Mexico City 14080, Mexico; enrique.garcia@cardiologia.org.mx (F.E.G.-A.); ggonzaga49@gmail.com (G.G.-S.); alejandro.vlz.orozco@gmail.com (K.A.V.-O.); yamniaalvarezalvarez@gmail.com (Y.Q.Á.-Á.); emilianoaparicio91@gmail.com (O.E.A.-T.); ediliatapia@hotmail.com (E.T.); horace\_33@yahoo.com.mx (H.O.-A.)
- <sup>3</sup> Division of Nephrology and Hypertension, Oregon Health Sciences University, Portland, OR 97239, USA; andreshe@ohsu.edu (A.A.-H.); lanaspá@ohsu.edu (M.A.L.)
- <sup>4</sup> Department of Nephrology, Rakuwakai Otowa Hospital, Kyoto 607-8062, Japan; nakagawt@gmail.com
- <sup>5</sup> Intensive Care Unit, Toranomon Hospital, Tokyo 105-8470, Japan; kuwamasa728@gmail.com
- <sup>6</sup> Department of Cardiology, Toranomon Hospital, Tokyo 105-8470, Japan
- <sup>7</sup> Division of Nephrology, Department of Internal Medicine, Koc University School of Medicine, Istanbul 34010, Turkey; mkanbay@ku.edu.tr
- \* Correspondence: laura.sanchez@cardiologia.org.mx



**Citation:** Johnson, R.J.; García-Arroyo, F.E.;

Gonzaga-Sánchez, G.; Vélez-Orozco, K.A.; Álvarez-Álvarez, Y.Q.; Aparicio-Trejo, O.E.; Tapia, E.; Osorio-Alonso, H.; Andrés-Hernando, A.; Nakagawa, T.; et al. Current Hydration Habits: The Disregarded Factor for the Development of Renal and Cardiometabolic Diseases. *Nutrients* **2022**, *14*, 2070. <https://doi.org/10.3390/nu14102070>

Academic Editor: Silvio Borrelli

Received: 7 March 2022

Accepted: 13 May 2022

Published: 15 May 2022

**Publisher's Note:** MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



**Copyright:** © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

**Abstract:** Improper hydration habits are commonly disregarded as a risk factor for the development of chronic diseases. Consuming an intake of water below recommendations (underhydration) in addition to the substitution of sugar-sweetened beverages (SSB) for water are habits deeply ingrained in several countries. This behavior is due to voluntary and involuntary dehydration; and because young children are exposed to SSB, the preference for a sweet taste is profoundly implanted in the brain. Underhydration and SSB intake lead to mild hyperosmolarity, which stimulates biologic processes, such as the stimulation of vasopressin and the polyol-fructose pathway, which restore osmolarity to normal but at the expense of the continued activation of these biological systems. Unfortunately, chronic activation of the vasopressin and polyol-fructose pathways has been shown to mediate many diseases, such as obesity, diabetes, metabolic syndrome, chronic kidney disease, and cardiovascular disease. It is therefore urgent that we encourage educational and promotional campaigns that promote the evaluation of personal hydration status, a greater intake of potable water, and a reduction or complete halting of the drinking of SSB.

**Keywords:** underhydration; water intake; metabolic syndrome; obesity; chronic kidney disease

## 1. Introduction

Healthy lifestyle factors provide benefit by both preventing and slowing the progression of non-communicable diseases [1]. While the role of a healthy diet and exercise are well-recognized [1], the role of water intake has been largely disregarded [2]. However, the intake of drinking water is critical to the maintaining of the osmolarity and concentrations of electrolytes needed to allow critical biochemical reactions to take place in both the intracellular and extracellular environment [3]. While it is well-recognized that the host can reduce water losses and accommodate in the setting of mild dehydration to maintain serum osmolarity, only recently has it been recognized that the chronic stimulation of biological responses to maintain osmolarity can have deleterious consequences on health [4,5]. This

suggests that ‘underhydration’, in which the activation of these biological processes results in normal serum osmolality, may represent an unrecognized but significant risk factor for disease. Until now, there has been some debate on this topic, as studies have found inconsistent findings [6]. Here, we briefly review the evidence presented by randomized trials, epidemiological studies, and basic science, indicating that suboptimal hydration, by chronically triggering the mechanisms aimed to preserve body water and protect against hypertonicity, i.e., vasopressin and the aldose reductase pathways, may be partially responsible for an increased tendency to develop chronic non-communicable diseases at younger ages.

## 2. Types of Dehydration

Dehydration usually refers to a loss of water resulting in an increase in serum and intracellular osmolality (hypertonic dehydration  $[\text{Na}^+] \geq 150 \text{ mEq/L}$  or  $\geq 300 \text{ mOsm/L}$ ), and it is associated with a reduction in intracellular volume [7]. Most commonly, dehydration occurs from either fluid restriction or water loss (such as in sweat or diarrhea) [7].

A biologically equivalent dehydration state may also occur through two other mechanisms. The first is by the ingestion of salt in the absence of drinking sufficient water to maintain isotonicity, leading to a condition of hyperosmolality and thirst [8]. The other mechanism is one that leads to a relative shift of water from the extracellular to the intracellular environment. One means is by drinking fructose-rich beverages, which leads to hyperosmolality by shifting water into the intracellular space, likely due to the increased intracellular glycogen synthesis that adsorbs water [9].

While dehydration refers to a relative reduction in the water to salt concentration in the extracellular environment, one can also lose salt, which is important in maintaining extracellular volume. When the extracellular volume level is low, it can lead to extracellular volume depletion and hypotension. Extracellular volume (ECV) depletion may also result in a greater loss of water, leading to both an increased serum osmolality and volume depletion (hypertonic volume depletion with serum sodium  $\geq 145 \text{ mEq/L}$ ), and then to volume depletion with normal serum osmolality (isotonic volume depletion with serum sodium  $[135\text{--}144 \text{ mEq/L}]$ ) or with a relatively greater loss of salt to water (hypotonic volume depletion with serum sodium  $<135 \text{ mEq/L}$ ). While dehydration is well-recognized in medicine, recently the condition of “underhydration” was coined by Kavouras [10] and further defined by Stookey as having serum sodium  $>145 \text{ mmol/L}$ , a first void urine volume  $<50 \text{ mL}$ , and/or spot urine osmolality  $\geq 500 \text{ mOsm/kg}$  [11]. In this condition, serum osmolality is maintained at the upper end of the normal range  $[270\text{--}290 \text{ mOsm/kg water}]$  at the cost of the chronic elevation of vasopressin and the activation of the renal mechanisms aimed toward the conservation of body water.

Underhydration is a common condition. A recent study found that over 95% of US adults (51–70 years old) were underhydrated; this condition was cross-sectionally associated with the increased prevalence in obesity, metabolic syndrome, insulin resistance, diabetes, high waist circumference, hypertension, and low high-density lipoproteins. After three to six years of follow-up, underhydrated subjects had a 4.21-fold higher risk of dying of chronic diseases [12]. Moreover, an analysis of a NHANES III sample reported a prevalence in elevated serum osmolality of 60% in older adults ( $\geq 295 \text{ mmol/L}$ ) [13].

## 3. What Constitutes an Adequate Water Intake?

In resting humans, there is a continuous loss of water through the process of respiration and through the skin; there is also an intermittent loss of water and electrolytes through the urinary and gastrointestinal tracts. Such a loss of water and electrolytes can be amplified by exercise and heat stress, as well as by not replacing such water losses. The oral intake of liquids and food is the primary means in humans by which to replenish water losses. Despite the importance of an adequate hydration status, there is not a worldwide consensus regarding how much water people should drink daily to maintain a healthy state of hydration [14].

Recently, recommendations for an adequate intake of water have been provided by the European Food Safety Authority (EFSA) [15] and by the Institute of Medicine (IOM) [16] in the USA (Table 1). In most countries, up to 80% of total water intake comes from fluid intake; therefore, the drinking of beverages represents the primary means to modulate total water intake.

**Table 1.** Adequate intake for fluids (mL/day) accordingly to EFSA [9] and IOM [10].

Age	EFSA	IOM
	mL/day	mL/day
0–12 months	680–800	700–800
1–3 years	1000	900
4–8 years	1200	1200
9–13 years:		
Male	1600	1800
Female	1500	1600
>14 years and adults:		
Male	2000	2600
Female	1600	1800

Based upon these recommendations, several epidemiological studies have found that the intake of water in many populations is inadequate. The NHANES III survey data, for example, estimated the prevalence of dehydration in adults to be 16–28% [13]. Another study that examined data from 13 countries from three continents suggested that underhydration was even more prevalent, with only 40% of males and 60% of females having a water intake within the recommended guidelines of the EFSA [17]. Another large cross-sectional survey that included 15 countries from three continents found that 47% of adults, 60% of children, and 75% of adolescents do not meet the EFSA recommendations for adequate fluid intake [18]. In addition, the use of biomarkers to classify hydration status suggests that water intake may be inadequate [19,20]. Subjects with obesity are also at a higher risk for being dehydrated than lean subjects [19].

Nevertheless, all of these studies carried some bias as they were based on self-completed surveys. On the other hand, the analysis of fluid intake based upon the biological markers of hydration status—such as serum or urine osmolality; plasma sodium concentration; urine volume, color, and specific gravity; and body weight changes—can provide more reliable data about body fluid composition. Based on such types of analyses, normal hydration has been defined as a urine osmolality between 500 mOsm/kg H<sub>2</sub>O and 800 mOsm/kg H<sub>2</sub>O [21–23]. Urine-specific gravity is another surrogate for hydration status that correlates with urine osmolality; a urine-specific gravity of 1.020 is considered the upper limit for normal hydration [24,25]. An easier way to detect hydration status that has gained popularity is the urine color chart developed by Armstrong for adults and Kavouras for children [26,27]. This method is an inexpensive and practical tool for evaluating hydration status and has been validated to correlate with body water deficits and to reflect changes in body water.

Low water consumption may be voluntary or involuntary [28,29]. Voluntary dehydration occurs despite adequate water availability and may relate to work conditions, lack of public toilet facilities, an inadequate response to thirst, lack of motivation, lack of a preference for water, and/or a preference for a sweet taste [30–34]. Voluntary dehydration in young children represents a special case, as they have a higher proportion of body water, making up 75% of their total body weight [35]; they also depend upon parents' or caregivers' encouragement to drink water. Thus, this population is especially at risk for underhydration [33]. On the other hand, involuntary dehydration is associated with the unavailability of clean tap water for intake [36] or an increased threshold for thirst, as happens with aging [37].

#### 4. Intake of Sweetened Beverages

The intake of fluids is highly affected by flavor both in children and adults [38–40]. Thus, children and adolescents have a marked preference for a sweet taste that is strengthened by early and frequent intake [41]. It has been shown that the consumption of sugar-sweetened beverages (SSB) during infancy is a predictor of later intake of SSB [42]. Experimental studies have shown that SSB intake during early life makes animals such as rats more susceptible to severe kidney injury following a bout of acute kidney injury in comparison to rats that received water [43]. Moreover, it has been reported that the stronger the preference for a sweet taste, the higher the intake of SSB [34].

The preference for sweets coupled with frequent early exposure to SSBs likely contribute to the increase in SSB consumption worldwide [44]. SSB include carbonated soft drinks, fruit drinks/juice, sports/energy drinks, and sugared coffee/tea drinks. In many regions, there are also culturally specific SSB, as is the case for “aguas frescas” in Mexico and some other Latin American countries [45]. Globally, North America and Latin America are the largest consumers of SSB [46]. SSB intake especially affects poorer communities, where it accounts for as much as from 10% to 23% of total calorie consumption [47].

In the United States, the intake of SSB has been decreasing in recent years [48]. However, more detailed analysis has shown that there are both regional and sociodemographic differences in SSB consumption patterns. High consumption rates for SSB remain in the South [49] and are also found among specific groups, including young adults, non-Hispanic blacks, Mexican Americans, and children and adults from low-income families [50,51]. In Latin America, more than 80% of Brazilian and Mexican adults drink one or more SSB per day, with lesser rates reported in Argentina and Uruguay [52]. On the other hand, Chile has the fastest absolute growth in SSB sales throughout the world [46].

High-income and middle-income countries have developed strategies to curtail the intake of SSB, including taxation, banning the sale of SSB in schools and other public institutions, restrictions on the marketing of SSB to children, front package labels, and public awareness campaigns [46]. Notably, a tax between 10 and 20% has been shown to be successful in decreasing the purchasing of SSB, while a tax of 30% markedly discourages the purchasing of SSB [53]. In Mexico, an SSB taxation rate of 10% resulted in a decrease of 9.5% in sales after two years, with the largest decrease found amongst the most socially disadvantaged households [54]. Likewise, the 25% tax imposed on SSB in Berkeley, California resulted in a 21% fall in sales in low-income neighborhoods within the first four months [55]. However, long-term epidemiological studies are needed to firmly establish whether taxation has the potential to reduce SSB intake. An additional consequence of taxing SSB is the encouragement to reformulate these products using a combination of sugars and nonnutritive sweeteners (NNS) to maintain the sweet flavor. Such action has unknown consequences in the long term, as there is some evidence that NNS can alter gut microbiota, brain response, and heart health [56].

High SSB intake is the main contributor to added sugar in the diet. Currently, there is strong evidence relating SSB intake to obesity, with an additional increased risk for those who have a genetic predisposition. Cardiometabolic diseases, metabolic syndrome, type 2 diabetes, non-alcoholic fatty liver disease, hypertension, gout, some forms of cancer, and cardiovascular mortality are also positively associated with SSB intake [57]. On the other hand, a well-designed clinical trial found that replacing SSB with non-caloric beverages diminished weight gain and fat accumulation [58]. However, it is important to notice that the deleterious effects of SSB are also causally linked to metabolic effects, such as fatty liver and diabetes, independently of weight gain.

#### 5. Metabolic, Cardiovascular, and Renal Effects Resulting from Poor Hydration Habits

Underhydration due to low water intake or recurrent mild dehydration is associated with the chronic activation of the renin-angiotensin system, endothelin, vasopressin, and the aldose reductase-fructokinase (AR-F) pathway [59,60]. While the renin-angiotensin and endothelin systems have been better characterized in acute hypohydration [61], the

present review will focus on the role of the vasopressin and AR-F pathways, as well as their interactions and synergistic effects.

### 5.1. Vasopressin Pathway

Vasopressin is a peptide hormone released by the posterior pituitary in response to an increase in plasma osmolality or a decrease in blood pressure. The primary known purpose of vasopressin is to decrease water loss by concentrating the urine through a mechanism that involves binding the V2 receptors in the collecting duct of the kidney [62]. There are also V2 receptors in the lungs, where they might reduce the loss of water vapor [63]. Thus, vasopressin is a critical hormone involved in protecting the organism from dehydration.

A recently recognized, novel role for vasopressin in the conservation of water has been that vasopressin may mediate the synthesis and storage of fat as a means of providing metabolic water [64]. Specifically, many animals, such as whales and desert mammals, metabolize their body fat as an additional source of water when fresh water is not easily available [65].

In humans, copeptin (the stable vasopressin analogue) concentrations in plasma have been found to be significantly associated with increased risk of type two diabetes, chronic kidney disease, and cardiovascular disease [66–69]. Moreover, low water intake, which induces chronic vasopressin secretion [70], predicts the development of risk factors for coronary artery disease, for example, hyperglycemia [71]. On the contrary, increasing water intake, a maneuver that decreases systemic copeptin concentrations [72,73], was found to protect against the development of metabolic syndrome and fatty liver in fructose-fed mice and in obese Zucker rats [64,73]. In humans, increasing water intake has also been associated with reduced concentrations of copeptin, fasting glucose, glycated Hb in men, and a lower type 2 diabetes risk [72,74–76]. Increased water intake has also been reported to lead to weight loss [77].

Chronic high levels of vasopressin may also have a role in driving kidney damage. There is early evidence that the chronic stimulation of vasopressin can accelerate kidney disease [78]. Experimentally, the chronic administration of desmopressin (a vasopressin V2 receptor agonist) induced albuminuria and kidney damage in rodents and humans [79,80]. Similarly, stimulation of the V1a receptor may cause renal vasoconstriction [81] as well as gluconeogenesis and glycogenolysis [5]; and coronary artery vasoconstriction [81].

Increased water intake, on the other hand, reduces the risk of albuminuria and CKD [82,83]; is inversely associated with CKD prevalence [84]; and is also associated with a favorable lipid profile, independently of physical activity and the intake of fats, protein, or fiber [85]. Despite these findings, in a randomized trial, stage three CKD patients reported that increasing water intake did not slow the progression of the disease. However, the increase in water intake achieved was relatively small (700 mL), and the study was underpowered to detect differences based on the small changes in copeptin (vasopressin) levels observed (−7% in coached patients) [86].

### 5.2. Aldose Reductase-Fructokinase (AR-F) Pathway

This pathway is mainly activated by hypertonic stress, hypoxia, and hyperglycemia [87]. Other mechanisms include hyperuricemia [88,89] and underhydration [43]. Overexpression of AR diverts glucose towards the aldose reductase pathway with the generation of sorbitol and fructose catalyzed by sorbitol dehydrogenase. The increase in endogenous fructose induces the activation of fructokinase, which is the limiting enzyme in fructose metabolism [90]. Increased fructokinase activity induces a temporary depletion in ATP from the synthesis of fructose-1P, because fructokinase metabolizes fructose so rapidly, in contrast to hexokinase [91]. Such an effect also depletes intracellular phosphorous, which induces the activation of AMP-deaminase 2 and the downstream degradation of purines with the increased synthesis of uric acid. This in turn inhibits AMP-kinase, inhibits aconitase-2 and enoyl-CoA hydratase in the Krebs cycle, activates NADPH oxidase, and diminishes nitric oxide bioavailability [92–94]. In the liver, these effects favor de novo lipogenesis



and block fatty acid oxidation, increase oxidative stress, promote insulin resistance, and induce liver steatosis and metabolic syndrome [92]. Increased serum osmolality induced by a high-sodium diet also activates the AR-F pathway and results in obesity, metabolic syndrome, and fatty liver [8].


In the kidney, dehydration may also activate the polyol-fructose pathway, where it may mediate kidney injury. Specifically, while aldose reductase is constitutively expressed in the renal medulla—where it produces sorbitol that acts as an osmotic agent to protect tubular cells from the hyperosmolar environment—it is normally not expressed in the renal cortex [87]. However, with dehydration, this enzyme is induced, and along with sorbitol dehydrogenase, results in fructose generation [87]. The proximal tubule contains fructokinase and can metabolize the fructose, leading to local oxidative stress and the release of inflammatory chemokines [95]. Local tubular damage can result and, in the setting of chronic heat stress and dehydration, may lead to chronic kidney disease that is fructokinase-dependent [96]. It has been proposed that this might be a mechanism for explaining the epidemics of CKD of unknown etiology that have emerged in Central America and elsewhere [97]. Thus, the activation of the AR-F pathway is also partially responsible for diabetic and recurrent dehydration nephropathies as well as acute kidney injury [43,90,96,98]. In addition, the uric acid generated during fructose metabolism induces endothelial dysfunction by decreasing the nitric oxide bioavailability and induces endothelial cell senescence while promoting vascular muscle cell hypertrophy, renin-angiotensin activation, and the systemic elevation of protein C reactive; such effects likely contribute to the development of hypertension [94,99].

In the heart, an increased AR-F pathway may also occur in response to ischemia from causes such as coronary artery disease, and there is evidence that this is responsible for cardiac remodeling and eventually, hypertrophy [100–102]. Collectively, the deleterious effects induced by the chronic activation of the AR-F pathway increase the probability of developing cardiovascular, renal, and metabolic diseases.

### 5.3. Synergy of the Vasopressin and AR-F Pathways

Both vasopressin and the AR-F pathways act in synergy, aggravating target organ damage. In fact, fructose has been found to directly stimulate vasopressin secretion [103,104]. SSB intake increases vasopressin (copeptin) concentrations in rats and humans exposed to heat stress, and it is associated with markers of kidney damage [60,105]. Wolf showed that a fructose infusion given to healthy men augmented vasopressin secretion, an effect not induced by an isotonic solution of glucose. Thus, the mechanism by which fructose stimulates vasopressin does not appear to become from its effects on osmolality [103], but rather from the metabolism of fructose in the hypothalamus [104]. Specifically, acutely dehydrating mice has been shown to induce the expression of aldose reductase of the polyol pathway in the supraoptic nuclei of the hypothalamus, followed by the production of fructose. In turn, the fructose is metabolized locally by fructokinase, which drives the synthesis of vasopressin [104]. Thus, mice lacking fructokinase show an impaired vasopressin response to dehydration [104]. Moreover, the oral ingestion of fructose in both laboratory animals [60,64,106] and humans [105,107] results in a rise in vasopressin (copeptin) levels in the blood. Thus, fructose metabolism is directly linked with the stimulation of the vasopressin system (Figure 1).

Consistent with these findings, recurrent heat-induced dehydration induced a lower secretion of copeptin in fructokinase knockout mice (FKM) compared to wild type mice, despite both groups having similar serum osmolality [96]. FKM were also protected from developing dehydration-induced chronic kidney disease. Importantly, it has been shown that, in both dehydrated and non-dehydrated rodents, plasma copeptin dose-dependently increased with fructose concentrations in drinking fluid without modifying serum or urine osmolality [64,108]. The stepped dose–response of copeptin to fructose concentrations was also associated with a stepped decline in kidney function [108] and stepped body adiposity [64].



**Figure 1.** Low water intake coupled with sugar-sweetened beverage (SSB) intake activate both vasopressin and the aldose reductase-fructokinase pathways, which also can synergize with each other, aggravating target organ damage. In the brain, milder increases in systemic osmolality due to dehydration induce the expression of the aldose reductase pathway in the supraoptic nuclei of the hypothalamus, followed by the production of fructose. In turn, the fructose is metabolized locally by fructokinase, driving the synthesis of vasopressin. The increased vasopressin activity stimulates V2R in the kidney, inducing urine concentration and chronically renal alterations. Stimulation of the V1b receptor occurs in the pancreatic islets as well as in the liver and the anterior pituitary, thereby stimulating the secretion of glucagon and the adrenocorticotropic hormone. V1bR stimulation also mediates fat production and other features of metabolic syndrome, such as fatty liver, obesity, and eventually, type 2 diabetes. Aldose reductase-fructokinase pathway activation induces an increase in uric acid synthesis which induces intracellular oxidative stress, mitochondrial alterations, and endothelial dysfunction. This eventually results in target organ damage, the organs that are more affected being the liver (fatty liver), heart (heart failure), kidney (chronic kidney disease) and the vessels (hypertension). High salt intake may lead to an increase in serum osmolality, thereby inducing chronic underhydration, activating both the polyol-fructose and vasopressin pathways. (Abbreviations: ACTH, adrenocorticotropic hormone; AR, aldose reductase; CKD, chronic kidney disease; HT, hypertension; POsm, Plasma osmolality; T2DM, type 2 diabetes mellitus).

We also found that fructose-induced metabolic syndrome was mediated by elevated vasopressin levels, which acted by stimulating the V1b receptor [64]. The mechanism is not totally known, but it may involve the stimulation of glucagon (via V1b receptors on the pancreatic islets) by the stimulation of ACTH from the V1b receptors on the anterior pituitary, or perhaps by direct stimulation of the liver itself [64]. Indeed, the stimulation of vasopressin 1b receptors was shown not only to mediate fat production (as a source of metabolic water) but also other features of the metabolic syndrome, thus suggesting a potential role for underhydration in the development of obesity and diabetes [64]. The

relevance of this finding is that people who are obese are frequently hyperosmolar and have high vasopressin levels (noted by elevations of copeptin, the stable analogue), likely because of diets rich in sugar and salt [109,110]. Underhydration is also substantially more common in this group than among the general population [12,19].

In this regard, we have found that a high salt diet (or dehydration itself) can induce both fructose and vasopressin formation [64,104,107]. Moreover, high salt intake may lead to increases in serum osmolality, thereby inducing chronic underhydration, activating both the polyol-fructose and vasopressin pathways. While high salt intake is linked with hypertension and cardiovascular events, salty diets also increase the risk for obesity and metabolic syndrome [8,110]. When laboratory animals are placed on a salty diet, they initially appear to be catabolic, but after a few months, they dramatically gain weight and develop the features of metabolic syndrome. The mechanism was shown to be mediated by the induction of the polyol-fructose pathway [8], and likely the vasopressin system as well. Consistent with these findings, we were able to show that a high level of salt intake also correlated with an increased risk for hepatic steatosis and for diabetes [8].

The AR-F and vasopressin pathways may also be involved in the pathogenesis of primary hypertension. As these pathways are driven more by osmolality than by salt content per se, it is of interest that serum sodium concentration is a better predictor for hypertension than total sodium intake [111]. Likewise, the acute ingestion of salt raises blood pressure and vasopressin levels in humans, but if it is accompanied by water intake that suppresses the rise in serum osmolality, no rise in blood pressure or vasopressin is observed [112]. Likewise, both fructose and uric acid (its metabolite) have been found to predict the development of hypertension [113,114]. Additionally, lowering uric acid has been reported to block the hypertensive response to fructose [115] and also to correct blood pressure in adolescents presenting with newly diagnosed primary hypertension [116,117].

Low water intake and increased consumption of SSB are habits which are typically rooted in infancy. We reported that underhydration induced by the chronic restriction of water intake in infant rats induced a greater secretion of copeptin and increased fructokinase expression in the kidney [43]; this effect was further amplified when rats were hydrated with SSB after water restriction. Moreover, in those rats, an event of acute kidney injury induced a catastrophic reduction of creatinine clearance and mortality, while animals rehydrated with water better endured the insult [43]. These data suggest that poor hydration habits activate vasopressin and AR-F pathways and that synergistically, these pathways lead to worse renal outcomes after an acute insult.

There is also evidence that vasopressin activates the AR-F pathway. For example, a chronic vasopressin blockade with conivaptan or tolvaptan prevented the overexpression of the components of the AR-F pathway in recurrently mildly heat-dehydrated rats that were rehydrated with 10% fructose and protected them from kidney damage [106,118]. Thus, vasopressin also regulates the expression of AR-F enzymes, at least in the context of mild dehydration. The exact mechanism concerning how vasopressin stimulates the AR-F pathway is not yet known, but the V2 receptor stimulation of cAMP and protein kinase A (PKA) can activate the tonicity-responsive enhancer/osmotic response element-binding protein (TonEBP/NFAT5) which regulates AR [119]. On the other hand, supplementation with antioxidants prevented the upregulation of AR-F enzymes in mildly dehydrated rats that were rehydrated with fructose [120] by preventing the nuclear translocation of the transcription factors responsible for AR and F, which are NFAT5 and ChREBP, respectively [120]. Since tolvaptan activates the nuclear factor erythroid 2-related factor (Nrf2) antioxidant pathway through the phosphorylation of protein kinase RNA-like endoplasmic reticulum kinase (PERK) [121], this can explain why this treatment also prevented the up-regulation of AR-F enzymes in a state of mild dehydration [118]. Such data strongly suggest that increased oxidative stress plays an important role in the crosstalk between the vasopressin and AR-F pathways. A summary of the interactions between vasopressin and AR-F pathways is depicted in Figure 1.



## 6. Conclusions and Recommendations

Physicians, and especially nephrologists, are trained to recognize dehydration and volume depletion and their acute health consequences. However, only recently has the concept of underhydration been recognized. For years, many of us were taught that the biological responses to dehydration that led to a correction of the dehydrated state simply reflected the exquisite ability of the kidney to ensure homeostasis, and the adage to drink a lot of water every day was not necessary to follow when such an eloquent organ as the kidney could fine tune our metabolism with ease. However, what we have learned is that the corrective pathways to maintain serum osmolarity, when they are chronically activated, carry a consequence, and this translates into an increased risk for obesity, metabolic syndrome, hypertension, and chronic kidney and heart disease. So, the concept of “hydration for health” should take on new meaning for the medical community today.

Therefore, we recommend educational campaigns to encourage people to evaluate their personal hydration status, for example, by checking urine color, and to encourage a greater intake of potable water. We also suggest educating parents and caregivers to prevent offering SSB during infancy and young childhood, as at these young ages the preference for a sweet taste is deeply implanted in the brain.

**Author Contributions:** Writing—original draft manuscript, R.J.J. and L.G.S.-L.; writing—reviewing and editing, F.E.G.-A., G.G.-S., K.A.V.-O., Y.Q.Á.-Á., O.E.A.-T., E.T., H.O.-A., A.A.-H., T.N., M.K. (Masanari Kuwabara), M.K. (Mehmet Kanbay) and M.A.L.; conceptualization, L.G.S.-L.; figure and table preparation, L.G.S.-L. All authors have read and agreed to the published version of the manuscript.

**Funding:** Part of the results presented in this publication were supported by Fondos de Gasto Directo Autorizados a la Subdirección de Investigación Básica del Instituto Nacional de Cardiología Ignacio Chávez and by NIH R01 DK125351 and NIH R01 DK121496 grants.

**Institutional Review Board Statement:** Not applicable.

**Informed Consent Statement:** Not applicable.

**Data Availability Statement:** Not applicable.

**Acknowledgments:** Kevin A. Vélez-Orozco is recipient of a fellowship from Dirección General de Calidad y Educación en Salud. Secretaría de Salud. México. Open access funding for this article was supported by Instituto Nacional de Cardiología Ignacio Chavez, México.

**Conflicts of Interest:** Richard J. Johnson has received honoraria from Horizon Pharma and Danone and is author of the book *Nature Wants Us to Be Fat* (Benbella books, 2022). Richard J. Johnson and Takahiko Nakagawa have stocks with XORTX Therapeutics. Richard J. Johnson, Miguel Lanaspá and Laura G. Sánchez-Lozada are members of Colorado Research Partners, a company dedicated to the generation of fructokinase inhibitors. The other authors declare no competing interest.

## References

1. Nyberg, S.T.; Singh-Manoux, A.; Pentti, J.; Madsen, I.E.H.; Sabia, S.; Alfredsson, L.; Bjorner, J.B.; Borritz, M.; Burr, H.; Goldberg, M.; et al. Association of Healthy Lifestyle with Years Lived Without Major Chronic Diseases. *JAMA Intern. Med.* **2020**, *180*, 760–768. [[CrossRef](#)] [[PubMed](#)]
2. Rush, E.C. Water: Neglected, unappreciated and under researched. *Eur. J. Clin. Nutr.* **2013**, *67*, 492–495. [[CrossRef](#)]
3. Kleiner, S.M. Water: An Essential but Overlooked Nutrient. *J. Am. Diet. Assoc.* **1999**, *99*, 200–206. [[CrossRef](#)]
4. Bouby, N.; Fernandes, S. Mild dehydration, vasopressin and the kidney: Animal and human studies. *Eur. J. Clin. Nutr.* **2003**, *57*, S39–S46. [[CrossRef](#)] [[PubMed](#)]
5. Vanhaecke, T.; Perrier, E.T.; Melander, O. A Journey through the Early Evidence Linking Hydration to Metabolic Health. *Ann. Nutr. Metab.* **2020**, *76*, 4–9. [[CrossRef](#)] [[PubMed](#)]
6. Stookey, J.J.D. Negative, Null and Beneficial Effects of Drinking Water on Energy Intake, Energy Expenditure, Fat Oxidation and Weight Change in Randomized Trials: A Qualitative Review. *Nutrients* **2016**, *8*, 19. [[CrossRef](#)]
7. Chevront, S.N.; Kenefick, R.W. Dehydration: Physiology, Assessment, and Performance Effects. *Compr. Physiol.* **2014**, *4*, 257–285. [[CrossRef](#)] [[PubMed](#)]

8. Lanaspá, M.A.; Kuwabara, M.; Andres-Hernando, A.; Li, N.; Cicerchi, C.; Jensen, T.; Orlicky, D.J.; Roncal-Jimenez, C.A.; Ishimoto, T.; Nakagawa, T.; et al. High salt intake causes leptin resistance and obesity in mice by stimulating endogenous fructose production and metabolism. *Proc. Natl. Acad. Sci. USA* **2018**, *115*, 3138–3143. [[CrossRef](#)]
9. Johnson, R.J.; Stenvinkel, P.; Andrews, P.; Sánchez-Lozada, L.G.; Nakagawa, T.; Gaucher, E.; Andres-Hernando, A.; Rodriguez-Iturbe, B.; Jimenez, C.R.; Garcia, G.; et al. Fructose metabolism as a common evolutionary pathway of survival associated with climate change, food shortage and droughts. *J. Intern. Med.* **2020**, *287*, 252–262. [[CrossRef](#)]
10. Kavouras, S.A. Hydration, dehydration, underhydration, optimal hydration: Are we barking up the wrong tree? *Eur. J. Nutr.* **2019**, *58*, 471–473. [[CrossRef](#)]
11. Stookey, J.D. Analysis of 2009–2012 Nutrition Health and Examination Survey (NHANES) Data to Estimate the Median Water Intake Associated with Meeting Hydration Criteria for Individuals Aged 12–80 Years in the US Population. *Nutrients* **2019**, *11*, 657. [[CrossRef](#)] [[PubMed](#)]
12. Stookey, J.D.; Kavouras, S.A.; Suh, H.; Lang, F. Underhydration Is Associated with Obesity, Chronic Diseases, and Death within 3 to 6 Years in the U.S. Population Aged 51–70 Years. *Nutrients* **2020**, *12*, 905. [[CrossRef](#)] [[PubMed](#)]
13. Stookey, J.D. High Prevalence of Plasma Hypertonicity among Community-Dwelling Older Adults: Results from NHANES III. *J. Am. Diet. Assoc.* **2005**, *105*, 1231–1239. [[CrossRef](#)] [[PubMed](#)]
14. Gandy, J. Water intake: Validity of population assessment and recommendations. *Eur. J. Nutr.* **2015**, *54*, 11–16. [[CrossRef](#)] [[PubMed](#)]
15. EFSA. Panel on Dietetic Products, Nutrition, and Allergies (NDA); Scientific Opinion on Dietary reference values for water. *EFSA J.* **2010**, *8*, 1459.
16. Institute of Medicine FaNB. *Dietary Reference Intakes for Water, Potassium, Sodium, Chloride and Sulfate*; National Academies Press: Washington, DC, USA, 2005; p. 638.
17. Pêgo, C.; Guelinckx, I.; Moreno, L.A.; Kavouras, S.; Gandy, J.J.; Martinez, H.; Bardosono, S.; Abdollahi, M.; Nasser, E.; Jarosz, A.; et al. Total fluid intake and its determinants: Cross-sectional surveys among adults in 13 countries worldwide. *Eur. J. Nutr.* **2015**, *54* (Suppl. 2), 35–43. [[CrossRef](#)] [[PubMed](#)]
18. Martinez, H.; Guelinckx, I.; Salas-Salvadó, J.; Gandy, J.; Kavouras, S.A.; Moreno, L.A. Harmonized Cross-Sectional Surveys Focused on Fluid Intake in Children, Adolescents and Adults: The Liq.In7 Initiative. *Ann. Nutr. Metab.* **2016**, *68* (Suppl. 2), 12–18. [[CrossRef](#)]
19. Stookey, J.D.; Barclay, D.; Arieff, A.; Popkin, B.M. The altered fluid distribution in obesity may reflect plasma hypertonicity. *Eur. J. Clin. Nutr.* **2007**, *61*, 190–199. [[CrossRef](#)]
20. Stookey, J.D.; Purser, J.L.; Pieper, C.F.; Cohen, H.J. Plasma hypertonicity: Another marker of frailty? *J. Am. Geriatr. Soc.* **2004**, *52*, 1313–1320. [[CrossRef](#)]
21. Stookey, J.D.; Brass, B.; Holliday, A.; Arieff, A. What is the cell hydration status of healthy children in the USA? Preliminary data on urine osmolality and water intake. *Public Health Nutr.* **2012**, *15*, 2148–2156. [[CrossRef](#)]
22. Bar-David, Y.; Urkin, J.; Landau, D.; Bar-David, Z.; Pilpel, D. Voluntary dehydration among elementary school children residing in a hot arid environment. *J. Hum. Nutr. Diet.* **2009**, *22*, 455–460. [[CrossRef](#)] [[PubMed](#)]
23. Manz, F.; Wentz, A. 24-h hydration status: Parameters, epidemiology and recommendations. *Eur. J. Clin. Nutr.* **2003**, *57* (Suppl. 2), S10–S18. [[CrossRef](#)] [[PubMed](#)]
24. Armstrong, L.E.; Herrera Soto, J.A.; Hacker, F.T.; Casa, D.J.; Kavouras, S.A.; Maresh, C.M. Urinary indices during dehydration, exercise, and rehydration. *Int. J. Sport Nutr.* **1998**, *8*, 345–355. [[CrossRef](#)] [[PubMed](#)]
25. Kavouras, S.A. Assessing hydration status. *Curr. Opin. Clin. Nutr. Metab. Care* **2002**, *5*, 519–524. [[CrossRef](#)]
26. Armstrong, L.E.; Maresh, C.M.; Castellani, J.W.; Bergeron, M.F.; Kenefick, R.W.; LaGasse, K.E.; Riebe, D. Urinary indices of hydration status. *Int. J. Sport Nutr.* **1994**, *4*, 265–279. [[CrossRef](#)]
27. Kavouras, S.A.; Johnson, E.C.; Bougatsas, D.; Arnaoutis, G.; Panagiotakos, D.B.; Perrier, E.; Klein, A. Validation of a urine color scale for assessment of urine osmolality in healthy children. *Eur. J. Nutr.* **2016**, *55*, 907–915. [[CrossRef](#)]
28. Urkin, J.; Bar-David, Y. Voluntary, Nonintentional Dehydration and Health. *Am. J. Public Health* **2015**, *105*, e7. [[CrossRef](#)]
29. Greenleaf, J.E. Problem: Thirst, drinking behavior, and involuntary dehydration. *Med. Sci. Sports Exerc.* **1992**, *24*, 645–656. [[CrossRef](#)]
30. Rodger, A.; Wehbe, L.H.; Papias, E.K. “I know it’s just pouring it from the tap, but it’s not easy”: Motivational processes that underlie water drinking. *Appetite* **2021**, *164*, 105249. [[CrossRef](#)]
31. Piil, J.F.; Lundbye-Jensen, J.; Christiansen, L.; Ioannou, L.; Tsoutsoubi, L.; Dallas, C.N.; Mantzios, K.; Flouris, A.D.; Nybo, L. High prevalence of hypohydration in occupations with heat stress—Perspectives for performance in combined cognitive and motor tasks. *PLoS ONE* **2018**, *13*, e0205321. [[CrossRef](#)]
32. Venugopal, V.; Rekha, S.; Manikandan, K.; Latha, P.K.; Vennila, V.; Ganesan, N.; Kumaravel, P.; Chinnadurai, S.J. Heat stress and inadequate sanitary facilities at workplaces—An occupational health concern for women? *Glob. Health Action* **2016**, *9*, 31945. [[CrossRef](#)] [[PubMed](#)]
33. Faidah, N.; Soraya, G.V.; Erlichster, M.; Natzir, R.; Chana, G.; Skafidas, E.; Hardjo, M.; Ganda, I.J.; Bahar, B. Detection of voluntary dehydration in paediatric populations using non-invasive point-of-care saliva and urine testing. *J. Paediatr. Child Health* **2021**, *57*, 813–818. [[CrossRef](#)] [[PubMed](#)]

34. Garneau, N.L.; Nuessle, T.M.; Mendelsberg, B.J.; Shepard, S.; Tucker, R.M. Sweet liker status in children and adults consequences for beverage intake in adults. *Food Qual. Prefer.* **2018**, *65*, 175–180. [[CrossRef](#)] [[PubMed](#)]
35. Powers, K.S. Dehydration: Isonatremic, Hyponatremic, and Hypernatremic Recognition and Management. *Pediatr. Rev.* **2015**, *36*, 274–283. [[CrossRef](#)]
36. Brooks, C.J.; Gortmaker, S.L.; Long, M.W.; Craddock, A.L.; Kenney, E.L. Racial ethnic and socioeconomic disparities in hydration status among us adults and the role of tap water and other beverage intake. *Am. J. Public Health* **2017**, *107*, 1387–1394. [[CrossRef](#)]
37. Phillips, P.A.; Rolls, B.J.; Ledingham, J.G.G.; Forsling, M.L.; Morton, J.J.; Crowe, M.J.; Wollner, L. Reduced thirst after water deprivation in healthy elderly men. *N. Engl. J. Med.* **1984**, *311*, 753–759. [[CrossRef](#)]
38. Block, J.P.; Gillman, M.W.; Linakis, S.K.; Goldman, R.E. “If it tastes good, I’m drinking it”: Qualitative study of beverage consumption among college students. *J. Adolesc. Health Off. Publ. Soc. Adolesc. Med.* **2013**, *52*, 702–706. [[CrossRef](#)]
39. Meyer, F.; Bar-Or, O.; Salsberg, A.; Passe, D. Hypohydration during exercise in children: Effect on thirst, drink preferences, and rehydration. *Int. J. Sport Nutr.* **1994**, *4*, 22–35. [[CrossRef](#)]
40. Battram, D.S.; Piche, L.; Beynon, C.; Kurtz, J.; He, M. Sugar-Sweetened Beverages: Children’s Perceptions, Factors of Influence, and Suggestions for Reducing Intake. *J. Nutr. Educ. Behav.* **2015**, *48*, 27–34. [[CrossRef](#)]
41. Vennerød, F.F.F.; Almli, V.L.; Berget, I.; Lien, N. Do parents form their children s sweet preference the role of parents and taste sensitivity on preferences for sweetness in pre schoolers. *Food Qual. Prefer.* **2017**, *62*, 172–182. [[CrossRef](#)]
42. Park, S.; Pan, L.; Sherry, B.; Li, R. The association of sugar sweetened beverage intake during infancy with sugar sweetened beverage intake at 6 years of age. *Pediatrics* **2014**, *134*, S56–S62. [[CrossRef](#)] [[PubMed](#)]
43. García-Arroyo, F.E.; Pérez-Estévez, H.E.; Tapia, E.; Gonzaga, G.; Muñoz-Jiménez, I.; Soto, V.; Sánchez-Lozada, L.G. Restricted Water Intake and Hydration with Fructose-Containing Beverages during Infancy Predispose to Aggravate an Acute Renal Ischemic Insult in Adolescent Rats. *Biomed. Res. Int.* **2020**, *2020*, 4281802. [[CrossRef](#)] [[PubMed](#)]
44. Singh, G.M.; Micha, R.; Khatibzadeh, S.; Shi, P.; Li, Y.; Andrews, K.G.; Engell, R.E.; Ezzati, M.; Mozaffarian, D. Global, Regional, and National Consumption of Sugar-Sweetened Beverages, Fruit Juices, and Milk: A Systematic Assessment of Beverage Intake in 187 Countries. *PLoS ONE* **2015**, *10*, e0124845. [[CrossRef](#)] [[PubMed](#)]
45. Bogart, L.M.; Cowgill, B.O.; Sharma, A.J.; Uyeda, K.; Sticklor, L.A.; Alijewicz, K.E.; Schuster, M.A. Parental and home environmental facilitators of sugar-sweetened beverage consumption among overweight and obese Latino youth. *Acad. Pediatr.* **2013**, *13*, 348–355. [[CrossRef](#)]
46. Popkin, B.M.; Hawkes, C. Sweetening of the global diet, particularly beverages: Patterns, trends, and policy responses. *Lancet Diabetes Endocrinol.* **2016**, *4*, 174–186. [[CrossRef](#)]
47. Bergallo, P.; Castagnari, V.; Fernández, A.; Mejía, R. Regulatory initiatives to reduce sugar-sweetened beverages (SSBs) in Latin America. *PLoS ONE* **2018**, *13*, e0205694. [[CrossRef](#)]
48. Sigala, D.M.; Stanhope, K.L. An Exploration of the Role of Sugar-Sweetened Beverage in Promoting Obesity and Health Disparities. *Curr. Obes. Rep.* **2021**, *10*, 39–52. [[CrossRef](#)]
49. Kumar, G.S.; Pan, L.; Park, S.; Leekwan, S.H.; Onufrak, S.; Blanck, H.M. Sugar sweetened beverage consumption among adults 18 states 2012. *Morb. Mortal. Wkly. Rep.* **2014**, *63*, 686–690.
50. Han, E.; Powell, L.M. Consumption patterns of sugar sweetened beverages in the united states. *J. Acad. Nutr. Diet.* **2013**, *113*, 43–53. [[CrossRef](#)]
51. Ogden, C.L.; Kit, B.K.; Carroll, M.D.; Park, S. Consumption of sugar drinks in the united states 2005–2008. In *NCHS Data Brief*; NCH: Highlandville, MD, USA, 2011; pp. 1–8.
52. Martinez, H.; Morin, C.; Gandy, J.; Carmuega, E.; Arredondo, J.L.; Pimentel, C.; Moreno, L.A.; Kavouras, S.A.; Salas-Salvadó, J.; Guelinckx, I. Fluid intake of Latin American adults: Results of four 2016 Liq.In 7 national cross-sectional surveys. *Eur. J. Nutr.* **2018**, *57*, 65–75. [[CrossRef](#)]
53. Redondo, M.; Hernández-Aguado, I.; Lumbreras, B. The impact of the tax on sweetened beverages: A systematic review. *Am. J. Clin. Nutr.* **2018**, *108*, 548–563. [[CrossRef](#)] [[PubMed](#)]
54. Colchero, M.A.; Rivera-Dommarco, J.; Popkin, B.M.; Ng, S.W. In Mexico, Evidence of Sustained Consumer Response Two Years After Implementing A Sugar-Sweetened Beverage Tax. *Health Aff. (Millwood)* **2017**, *36*, 564–571. [[CrossRef](#)] [[PubMed](#)]
55. Falbe, J.; Thompson, H.R.; Becker, C.M.; Rojas, N.; McCulloch, C.E.; Madsen, K.A. Impact of the Berkeley Excise Tax on Sugar-Sweetened Beverage Consumption. *Am. J. Public Health* **2016**, *106*, 1865–1871. [[CrossRef](#)] [[PubMed](#)]
56. Popkin, B.M.; Ng, S.W. Sugar-sweetened beverage taxes: Lessons to date and the future of taxation. *PLoS Med.* **2021**, *18*, e1003412. [[CrossRef](#)] [[PubMed](#)]
57. Malik, V.S.; Hu, F.B. The role of sugar-sweetened beverages in the global epidemics of obesity and chronic diseases. *Nat. Rev. Endocrinol.* **2022**, *18*, 205–218. [[CrossRef](#)]
58. De Ruyter, J.C.; Olthof, M.R.; Seidell, J.C.; Katan, M.B. A trial of sugar-free or sugar-sweetened beverages and body weight in children. *N. Engl. J. Med.* **2012**, *367*, 1397–1406. [[CrossRef](#)]
59. García-Arroyo, F.E.; Tapia, E.; Muñoz-Jiménez, I.; Gonzaga-Sánchez, G.; Arellano-Buendía, A.S.; Osorio-Alonso, H.; Manterola-Romero, L.; Roncal-Jiménez, C.A.; Johnson, R.J.; Sánchez-Lozada, L.G. Fluid Intake Restriction Concomitant to Sweetened Beverages Hydration Induce Kidney Damage. *Oxid. Med. Cell. Longev.* **2020**, *2020*, 8850266. [[CrossRef](#)]

60. Garcia, F.; Cristóbal, M.; Arellano-Buendía, A.S.; Osorio, H.; Tapia, E.; Soto, V.; Madero, M.; Lanaspá, M.A.; Roncal-Jiménez, C.; Bankir, L.; et al. Rehydration with soft drink-like beverages exacerbates dehydration and worsens dehydration-associated renal injury. *Am. J. Physiol. Integr. Comp. Physiol.* **2016**, *311*, R57–R65. [[CrossRef](#)]
61. Watso, J.C.; Farquhar, W.B. Hydration Status and Cardiovascular Function. *Nutrients* **2019**, *11*, 1866. [[CrossRef](#)]
62. Bankir, L.; Bichet, D.G.; Morgenthaler, N.G. Vasopressin: Physiology, assessment and osmosensation. *J. Intern. Med.* **2017**, *282*, 284–297. [[CrossRef](#)]
63. Fay, M.J.; Du, J.; Yu, X.; North, W.G. Evidence for expression of vasopressin V2 receptor mRNA in human lung. *Peptides* **1996**, *17*, 477–481. [[CrossRef](#)]
64. Andres-Hernando, A.; Jensen, T.J.; Kuwabara, M.; Orlicky, D.J.; Cicerchi, C.; Li, N.; Roncal-Jimenez, C.A.; Garcia, G.E.; Ishimoto, T.; Maclean, P.S.; et al. Vasopressin mediates fructose-induced metabolic syndrome by activating the V1b receptor. *JCI Insight.* **2021**, *6*, e140848. [[CrossRef](#)] [[PubMed](#)]
65. Johnson, R.J.; Stenvinkel, P.; Jensen, T.; Lanaspá, M.A.; Roncal, C.; Song, Z.; Bankir, L.; Sanchez-Lozada, L.-G. Metabolic and Kidney Diseases in the Setting of Climate Change, Water Shortage, and Survival Factors. *J. Am. Soc. Nephrol.* **2016**, *27*, 2247–2256. [[CrossRef](#)] [[PubMed](#)]
66. Tasevska, I.; Enhörning, S.; Christensson, A.; Persson, M.; Nilsson, P.M.; Melander, O. Increased Levels of Copeptin, a Surrogate Marker of Arginine Vasopressin, Are Associated with an Increased Risk of Chronic Kidney Disease in a General Population. *Am. J. Nephrol.* **2016**, *44*, 22–28. [[CrossRef](#)] [[PubMed](#)]
67. Roussel, R.; El Boustany, R.; Bouby, N.; Potier, L.; Fumeron, F.; Mohammedi, K.; Balkau, B.; Tichet, J.; Bankir, L.; Marre, M.; et al. Plasma copeptin avp gene variants and incidence of type 2 diabetes in a cohort from the community. *J. Clin. Endocrinol. Metab.* **2016**, *101*, 2432–2439. [[CrossRef](#)] [[PubMed](#)]
68. Tasevska, I.; Enhörning, S.; Persson, M.; Nilsson, P.M.; Melander, O. Copeptin predicts coronary artery disease cardiovascular and total mortality. *Heart* **2016**, *102*, 127–132. [[CrossRef](#)] [[PubMed](#)]
69. Butler-Dawson, J.; Dally, M.; Johnson, R.J.; Johnson, E.C.; Krisher, L.; Sánchez-Lozada, L.-G.; Griffin, B.R.; Brindley, S.; Newman, L.S. Association of Copeptin, a Surrogate Marker of Arginine Vasopressin, with Decreased Kidney Function in Sugarcane Workers in Guatemala. *Ann. Nutr. Metab.* **2020**, *76*, 30–36. [[CrossRef](#)]
70. Perrier, E.; Vergne, S.; Klein, A.; Poupin, M.; Rondeau, P.; Le Bellego, L.; Armstrong, L.E.; Lang, F.; Stookey, J.; Tack, I. Hydration biomarkers in free-living adults with different levels of habitual fluid consumption. *Br. J. Nutr.* **2013**, *109*, 1678–1687. [[CrossRef](#)]
71. Roussel, R.; Fezeu, L.; Bouby, N.; Balkau, B.; Lantieri, O.; Alhenc-Gelas, F.; DESIR Study Group. Low water intake and risk for new-onset hyperglycemia. *Diabetes Care* **2011**, *34*, 2551–2554. [[CrossRef](#)]
72. Lemetais, G.; Melander, O.; Vecchio, M.; Bottin, J.H.; Enhörning, S.; Perrier, E.T. Effect of increased water intake on plasma copeptin in healthy adults. *Eur. J. Nutr.* **2018**, *57*, 1883–1890. [[CrossRef](#)]
73. Taveau, C.; Chollet, C.; Waeckel, L.; Desposito, D.; Bichet, D.-G.; Arthus, M.-F.; Magnan, C.; Philippe, E.; Paradis, V.; Foufelle, F.; et al. Vasopressin and hydration play a major role in the development of glucose intolerance and hepatic steatosis in obese rats. *Diabetologia* **2015**, *58*, 1081–1090. [[CrossRef](#)] [[PubMed](#)]
74. Enhörning, S.; Brunkwall, L.; Tasevska, I.; Ericson, U.; Tholin, J.P.; Persson, M.; Lemetais, G.; Vanhaecke, T.; Dolci, A.; Perrier, E.T.; et al. Water Supplementation Reduces Copeptin and Plasma Glucose in Adults with High Copeptin: The H2O Metabolism Pilot Study. *J. Clin. Endocrinol. Metab.* **2019**, *1045*, 1917–1925. [[CrossRef](#)] [[PubMed](#)]
75. Carroll, H.A.; Betts, J.A.; Johnson, L. An investigation into the relationship between plain water intake and glycated Hb (HbA1c): A sex-stratified, cross-sectional analysis of the UK National Diet and Nutrition Survey (2008–2012). *Br. J. Nutr.* **2016**, *116*, 1–11. [[CrossRef](#)] [[PubMed](#)]
76. Carroll, H.A.; Davis, M.G.; Papadaki, A. Higher plain water intake is associated with lower type 2 diabetes risk: A cross-sectional study in humans. *Nutr. Res.* **2015**, *35*, 865–872. [[CrossRef](#)]
77. Stookey, J.D.; Constant, F.; Popkin, B.M.; Gardner, C.D. Drinking water is associated with weight loss in overweight dieting women independent of diet and activity. *Obesity (Silver Spring)* **2008**, *16*, 2481–2488. [[CrossRef](#)]
78. Bouby, N.; Bachmann, S.; Bichet, D.; Bankir, L. Effect of water intake on the progression of chronic renal failure in the 5/6 nephrectomized rat. *Am. J. Physiol.* **1990**, *258 Pt 2*, F973–F979. [[CrossRef](#)]
79. Bardoux, P.; Bichet, D.G.; Martin, H.; Gallois, Y.; Marre, M.; Arthus, M.-F.; Lonergan, M.; Ruel, N.; Bouby, N.; Bankir, L. Vasopressin increases urinary albumin excretion in rats and humans: Involvement of V2 receptors and the renin-angiotensin system. *Nephrol. Dial. Transplant. Off. Publ. Eur. Dial. Transpl. Assoc.—Eur. Ren. Assoc.* **2003**, *18*, 497–506. [[CrossRef](#)]
80. Roncal-Jimenez, C.A.; Milagres, T.; Andres-Hernando, A.; Kuwabara, M.; Jensen, T.; Song, Z.; Bjornstad, P.; Garcia, G.E.; Sato, Y.; Sanchez-Lozada, L.G.; et al. Effects of exogenous desmopressin on a model of heat stress nephropathy in mice. *Am. J. Physiol. Ren. Physiol.* **2017**, *312*, F418–F426. [[CrossRef](#)]
81. Walker, B.R.; Childs, M.E.; Adams, E.M. Direct cardiac effects of vasopressin role of v1 and v2 vasopressinergic receptors. *Am. J. Physiol. Heart Circ. Physiol.* **1988**, *255*, H261–H265. [[CrossRef](#)]
82. Wang, H.W.; Jiang, M.Y. Higher volume of water intake is associated with lower risk of albuminuria and chronic kidney disease. *Medicine* **2021**, *21*, e26009. [[CrossRef](#)]
83. Clark, W.F.; Sontrop, J.M.; Macnab, J.J.; Suri, R.; Moist, L.; Salvadori, M.; Garg, A.X. Urine volume and change in estimated GFR in a community-based cohort study. *Clin. J. Am. Soc. Nephrol. CJASN* **2011**, *6*, 2634–2641. [[CrossRef](#)] [[PubMed](#)]



84. Sontrop, J.M.; Dixon, S.N.; Garg, A.X.; Buendia-Jimenez, I.; Dohein, O.; Huang, S.-H.S.; Clark, W.F. Association between water intake, chronic kidney disease, and cardiovascular disease: A cross-sectional analysis of NHANES data. *Am. J. Nephrol.* **2013**, *37*, 434–442. [[CrossRef](#)] [[PubMed](#)]
85. Brunkwall, L.; Ericson, U.; Nilsson, P.M.; Enhörning, S. High water intake and low urine osmolality are associated with favorable metabolic profile at a population level: Low vasopressin secretion as a possible explanation. *Eur. J. Nutr.* **2020**, *59*, 3715–3722. [[CrossRef](#)] [[PubMed](#)]
86. Clark, W.F.; Sontrop, J.M.; Huang, S.H.; Gallo, K.; Moist, L.; House, A.A.; Cuerden, M.S.; Weir, M.A.; Bagga, A.; Brimble, S.; et al. Effect of Coaching to Increase Water Intake on Kidney Function Decline in Adults with Chronic Kidney Disease: The CKD WIT Randomized Clinical Trial. *JAMA* **2018**, *319*, 1870–1879. [[CrossRef](#)]
87. Andres-Hernando, A.; Johnson, R.J.; Lanaspas, M.A. Endogenous fructose production: What do we know and how relevant is it? *Curr. Opin. Clin. Nutr. Metab. Care* **2019**, *22*, 289–294. [[CrossRef](#)]
88. Sanchez-Lozada, L.-G.; Andres-Hernando, A.; Garcia, F.; Cicerchi, C.; Li, N.; Kuwabara, M.; Roncal-Jimenez, C.A.; Johnson, R.J.; Lanaspas, M.A. Uric acid activates aldose reductase and the polyol pathway for endogenous fructose and fat production causing development of fatty liver in rats. *J. Biol. Chem.* **2019**, *294*, 4272–4281. [[CrossRef](#)]
89. Huang, Z.; Hong, Q.; Zhang, X.; Xiao, W.; Wang, L.; Cui, S.; Feng, Z.; Lv, Y.; Cai, G.; Chen, X.; et al. Aldose reductase mediates endothelial cell dysfunction induced by high uric acid concentrations. *Cell Commun. Signal* **2017**, *15*, 3. [[CrossRef](#)]
90. Lanaspas, M.A.; Ishimoto, T.; Cicerchi, C.; Tamura, Y.; Roncal-Jimenez, C.A.; Chen, W.; Tanabe, K.; Andres-Hernando, A.; Orlicky, D.J.; Finol, E.; et al. Endogenous fructose production and fructokinase activation mediate renal injury in diabetic nephropathy. *J. Am. Soc. Nephrol.* **2014**, *25*, 2526–2538. [[CrossRef](#)]
91. Hallfrisch, J. Metabolic effects of dietary fructose. *FASEB J.* **1990**, *4*, 2652–2660. [[CrossRef](#)]
92. Lanaspas, M.A.; Cicerchi, C.; Garcia, G.; Li, N.; Roncal-Jimenez, C.A.; Rivard, C.J.; Hunter, B.; Andrés-Hernando, A.; Ishimoto, T.; Sánchez-Lozada, L.G.; et al. Counteracting roles of AMP deaminase and AMP kinase in the development of fatty liver. *PLoS ONE* **2012**, *7*, e48801. [[CrossRef](#)]
93. Lanaspas, M.A.; Sanchez-Lozada, L.G.; Choi, Y.J.; Cicerchi, C.; Kanbay, M.; Roncal-Jimenez, C.A.; Ishimoto, T.; Li, N.; Marek, G.; Duranay, M.; et al. Uric acid induces hepatic steatosis by generation of mitochondrial oxidative stress: Potential role in fructose-dependent and -independent fatty liver. *J. Biol. Chem.* **2012**, *287*, 40732–40744. [[CrossRef](#)] [[PubMed](#)]
94. Khosla, U.M.; Zharikov, S.; Finch, J.L.; Nakagawa, T.; Roncal, C.; Mu, W.; Krotova, K.; Block, E.R.; Prabhakar, S.; Johnson, R.J. Hyperuricemia induces endothelial dysfunction. *Kidney Int.* **2005**, *67*, 1739–1742. [[CrossRef](#)] [[PubMed](#)]
95. Cirillo, P.; Gersch, M.S.; Mu, W.; Scherer, P.M.; Kim, K.M.; Gesualdo, L.; Henderson, G.N.; Johnson, R.J.; Sautin, Y.Y. Ketohexokinase-dependent metabolism of fructose induces proinflammatory mediators in proximal tubular cells. *J. Am. Soc. Nephrol.* **2009**, *20*, 545–553. [[CrossRef](#)] [[PubMed](#)]
96. Roncal Jimenez, C.A.; Ishimoto, T.; Lanaspas, M.A.; Rivard, C.J.; Nakagawa, T.; Ejaz, A.A.; Cicerchi, C.; Inaba, S.; Le, M.; Miyazaki, M.; et al. Fructokinase activity mediates dehydration-induced renal injury. *Kidney Int.* **2014**, *86*, 294–302. [[CrossRef](#)]
97. Glaser, J.; Lemery, J.; Rajagopalan, B.; Diaz, H.F.; García-Trabanino, R.; Taduri, G.; Madero, M.; Amarasinghe, M.; Abraham, G.; Anutrakulchai, S.; et al. Climate Change and the Emergent Epidemic of CKD from Heat Stress in Rural Communities: The Case for Heat Stress Nephropathy. *Clin. J. Am. Soc. Nephrol. CJASN* **2016**, *11*, 1472–1483. [[CrossRef](#)]
98. Andres-Hernando, A.; Li, N.; Cicerchi, C.; Inaba, S.; Chen, W.; Roncal-Jimenez, C.; Le, M.T.; Wempe, M.F.; Milagres, T.; Ishimoto, T.; et al. Protective role of fructokinase blockade in the pathogenesis of acute kidney injury in mice. *Nat. Commun.* **2017**, *8*, 14181. [[CrossRef](#)]
99. Kang, D.H.; Park, S.K.; Lee, I.K.; Johnson, R.J. Uric Acid-Induced C-Reactive Protein Expression: Implication on Cell Proliferation and Nitric Oxide Production of Human Vascular Cells. *J. Am. Soc. Nephrol.* **2005**, *16*, 3553–3562. [[CrossRef](#)]
100. Hwang, Y.C.; Sato, S.; Tsai, J.Y.; Yan, S.; Bakr, S.; Zhang, H.; Oates, P.J.; Ramasamy, R. Aldose reductase activation is a key component of myocardial response to ischemia. *FASEB J.* **2002**, *16*, 243–245. [[CrossRef](#)]
101. Hwang, Y.C.; Bakr, S.; Ellery, C.A.; Oates, P.J.; Ramasamy, R. Sorbitol dehydrogenase: A novel target for adjunctive protection of ischemic myocardium. *FASEB J.* **2003**, *17*, 2331–2333. [[CrossRef](#)]
102. Mirtschink, P.; Krishnan, J.; Grimm, F.; Sarre, A.; Hörl, M.; Kayikci, M.; Fankhauser, N.; Christinat, Y.; Cortijo, C.; Feehan, O.; et al. HIF-driven SF3B1 induces KHK-C to enforce fructolysis and heart disease. *Nature* **2015**, *522*, 444–449. [[CrossRef](#)]
103. Wolf, J.P.; Nguyen, N.U.; Dumoulin, G.; Berthelay, S. Influence of hypertonic monosaccharide infusions on the release of plasma arginine vasopressin in normal humans. *Horm. Metab. Res. = Hormon- und Stoffwechselforschung = Horm. Metab.* **1992**, *24*, 379–383. [[CrossRef](#)] [[PubMed](#)]
104. Song, Z.; Roncal-Jimenez, C.A.; Lanaspas-Garcia, M.A.; Oppelt, S.A.; Kuwabara, M.; Jensen, T.; Milagres, T.; Andres-Hernando, A.; Ishimoto, T.; Garcia, G.E.; et al. Role of fructose and fructokinase in acute dehydration-induced vasopressin gene expression and secretion in mice. *J. Neurophysiol.* **2017**, *117*, 646–654. [[CrossRef](#)] [[PubMed](#)]
105. Chapman, C.L.; Johnson, B.D.; Sackett, J.R.; Parker, M.D.; Schlader, Z.J. Soft drink consumption during and following exercise in the heat elevates biomarkers of acute kidney injury. *Am. J. Physiol. Regul. Integr. Comp. Physiol.* **2019**, *316*, R189–R198. [[CrossRef](#)] [[PubMed](#)]
106. García-Arroyo, F.E.; Tapia, E.; Blas-Marron, M.G.; Gonzaga, G.; Silverio, O.; Cristóbal, M.; Osorio, H.; Arellano-Buendía, A.S.; Zazueta, C.; Aparicio-Trejo, O.E.; et al. Vasopressin Mediates the Renal Damage Induced by Limited Fructose Rehydration in Recurrently Dehydrated Rats. *Int. J. Biol. Sci.* **2017**, *13*, 961–975. [[CrossRef](#)]



107. Kanbay, M.; Guler, B.; Ertuglu, L.; Dage, T.; Afsar, B.; Incir, S.; Baygul, A.; Covic, A.; Andres-Hernando, A.; Sánchez-Lozada, L.; et al. The Speed of Ingestion of a Sugary Beverage Has an Effect on the Acute Metabolic Response to Fructose. *Nutrients* **2021**, *13*, 1916. [[CrossRef](#)]
108. Sanchez-Lozada, L.G.; García-Arroyo, F.E.; Gonzaga, G.; Blas-Marron, M.G.; Silverio, O.; Muñoz, I.; Tapia, E.; Johnson, R.J. Heat-Induced Renal Damage (HRD) Is Dose-Dependently Worsened by Fructose (F) Concentration in Rehydration Fluid. *J. Am. Soc. Nephrol.* **2017**, *28*, 772.
109. Malik, V.S.; Hu, F.B. Fructose and Cardiometabolic Health: What the Evidence from Sugar-Sweetened Beverages Tells Us. *J. Am. Coll. Cardiol.* **2015**, *66*, 1615–1624. [[CrossRef](#)]
110. Libuda, L.; Kersting, M.; Alexy, U. Consumption of dietary salt measured by urinary sodium excretion and its association with body weight status in healthy children and adolescents. *Public Health Nutr.* **2012**, *15*, 433–441. [[CrossRef](#)]
111. Kuwabara, M.; Hisatome, I.; Roncal-Jimenez, C.A.; Niwa, K.; Andres-Hernando, A.; Jensen, T.; Bjornstad, P.; Milagres, T.; Cicerchi, C.; Song, Z.; et al. Increased Serum Sodium and Serum Osmolarity Are Independent Risk Factors for Developing Chronic Kidney Disease; 5 Year Cohort Study. *PLoS ONE* **2017**, *12*, e0169137. [[CrossRef](#)]
112. Kuwabara, M.; Kanbay, M.; Niwa, K.; Ae, R.; Andres-Hernando, A.; Roncal-Jimenez, C.; Garcia, G.; Sánchez-Lozada, L.; Rodriguez-Iturbe, B.; Hisatome, I.; et al. Hyperosmolarity and Increased Serum Sodium Concentration Are Risks for Developing Hypertension Regardless of Salt Intake: A Five-Year Cohort Study in Japan. *Nutrients* **2020**, *12*, 1422. [[CrossRef](#)]
113. Jalal, D.I.; Smits, G.; Johnson, R.J.; Chonchol, M. Increased fructose associates with elevated blood pressure. *J. Am. Soc. Nephrol.* **2010**, *21*, 1543–1549. [[CrossRef](#)] [[PubMed](#)]
114. Feig, D.I.; Madero, M.; Jalal, D.I.; Sanchez-Lozada, L.G.; Johnson, R.J. Uric acid and the origins of hypertension. *J. Pediatr.* **2013**, *162*, 896–902. [[CrossRef](#)] [[PubMed](#)]
115. Perez-Pozo, S.E.; Schold, J.; Nakagawa, T.; Sanchez-Lozada, L.G.; Johnson, R.J.; Lillo, J.L. Excessive fructose intake induces the features of metabolic syndrome in healthy adult men: Role of uric acid in the hypertensive response. *Int. J. Obes. (Lond.)* **2010**, *34*, 454–461. [[CrossRef](#)] [[PubMed](#)]
116. Feig, D.I.; Soletsky, B.; Johnson, R.J. Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: A randomized trial. *JAMA* **2008**, *300*, 924–932. [[CrossRef](#)]
117. Soletsky, B.; Feig, D.I. Uric acid reduction rectifies prehypertension in obese adolescents. *Hypertension* **2012**, *60*, 1148–1156. [[CrossRef](#)]
118. García-Arroyo, F.E.; Muñoz-Jiménez, I.; Gonzaga, G.; Tapia, E.; Osorio-Alonso, H.; A Roncal-Jiménez, C.; Iroz, A.; Vecchio, M.; Reyes-García, J.G.; Johnson, R.J.; et al. A Role for Both V1a and V2 Receptors in Renal Heat Stress Injury Amplified by Rehydration with Fructose. *Int. J. Mol. Sci.* **2019**, *20*, 5764. [[CrossRef](#)]
119. Ferraris, J.D.; Persaud, P.; Williams, C.K.; Chen, Y.; Burg, M.B. cAMP-independent role of PKA in tonicity-induced transactivation of tonicity-responsive enhancer/ osmotic response element-binding protein. *Proc. Natl. Acad. Sci. USA* **2002**, *99*, 16800–16805. [[CrossRef](#)]
120. García-Arroyo, F.E.; Gonzaga, G.; Muñoz-Jiménez, I.; Osorio-Alonso, H.; Iroz, A.; Vecchio, M.; Tapia, E.; Roncal-Jiménez, C.A.; Johnson, R.J.; Sánchez-Lozada, L.G. Antioxidant supplements as a novel mean for blocking recurrent heat stress-induced kidney damage following rehydration with fructose-containing beverages. *Free Radic. Biol. Med.* **2019**, *141*, 182–191. [[CrossRef](#)]
121. Fujiki, T.; Ando, F.; Murakami, K.; Isobe, K.; Mori, T.; Susa, K.; Nomura, N.; Sohara, E.; Rai, T.; Uchida, S. Tolvaptan activates the Nrf2/HO-1 antioxidant pathway through PERK phosphorylation. *Sci. Rep.* **2019**, *9*, 9245. [[CrossRef](#)]